N-[4-(3-amino-1,2-benzisoxazol-4-yl)phenyl]-N'-(3,5-dimethylphenyl)urea | 819057-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(3-amino-1,2-benzisoxazol-4-yl)phenyl]-N'-(3,5-dimethylphenyl)urea
• 英文别名: 3-[4-(3-Amino-1,2-benzoxazol-4-yl)phenyl]-1-(3,5-dimethylphenyl)urea；1-[4-(3-amino-1,2-benzoxazol-4-yl)phenyl]-3-(3,5-dimethylphenyl)urea
• CAS: 819057-52-8
• 化学式: C₂₂H₂₀N₄O₂
• 分子量: 372.426
• InChiKey: DLPARMNJOHFOLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  93.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(4-aminophenyl)-1,2-benzoisooxazol-3-amine 、 3,5-二甲基苯基异氰酸酯 以 二氯甲烷 为溶剂， 生成 N-[4-(3-amino-1,2-benzisoxazol-4-yl)phenyl]-N'-(3,5-dimethylphenyl)urea
  参考文献：
  名称：

  3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases

  摘要：

  A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[d]isoxazoles, incorporating a N,N'-diphenyl urea moiety of the 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs. Within this series, orally bioavailable compounds possessing promising pharmacokinetic profiles were identified, and a number of compounds demonstrated in vivo efficacy in models of VEGF-stimulated vascular permeability and tumor growth. In particular, compound 50 exhibited an ED50 of 2.0 mg/kg in the VEGF-stimulated uterine edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given orally at a dose of 10 mg/kg/day.

  DOI：

  10.1021/jm701096v

文献信息

• Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
  申请人：Dai Yujia

  公开号：US20050020603A1

  公开（公告）日：2005-01-27

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶很有用。本发明还揭示了制备这些化合物的方法，包含这些化合物的组合物以及使用这些化合物的治疗方法。
• INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS
  申请人：Dai Yujia

  公开号：US20080076767A1

  公开（公告）日：2008-03-27

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法，含有这些化合物的组合物以及使用这些化合物的治疗方法。
• Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors
  申请人：Novartis AG

  公开号：EP2594264A1

  公开（公告）日：2013-05-22

  The present invention provides compositions and methods for treating ocular neovascularization, angiogenesis, retinal edema, diabetic retinopathy, and/or retinal ischemia in order to prevent the loss of visual acuity associated with such conditions. More specifically, the present invention provides compositions containing receptor tyrosine kinase (RTK) inhibitors having unique binding profiles and their use in treating ocular disorders.

  本发明提供了治疗眼部新生血管、血管生成、视网膜水肿、糖尿病视网膜病变和/或视网膜缺血的组合物和方法，以防止与此类病症相关的视力丧失。更具体地说，本发明提供了含有具有独特结合谱的受体酪氨酸激酶（RTK）抑制剂的组合物及其在治疗眼部疾病中的用途。
• Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
  申请人：Bingaman P. David

  公开号：US20060189608A1

  公开（公告）日：2006-08-24

  The present invention provides compositions and methods for treating ocular neovascularization, angiogenesis, retinal edema, diabetic retinopathy, and/or retinal ischemia in order to prevent the loss of visual acuity associated with such conditions. More specifically, the present invention provides compositions containing receptor tyrosine kinase (RTK) inhibitors having unique binding profiles and their use in treating ocular disorders.

  本发明提供了治疗眼部新生血管、血管生成、视网膜水肿、糖尿病视网膜病变和/或视网膜缺血的组合物和方法，以防止与此类病症相关的视力丧失。更具体地说，本发明提供了含有具有独特结合谱的受体酪氨酸激酶（RTK）抑制剂的组合物及其在治疗眼部疾病中的用途。
• SOLID DISPERSION PRODUCT OF N-ARYL UREA-BASED DRUGS
  申请人：Abbott GmbH & Co. KG

  公开号：EP2197425A2

  公开（公告）日：2010-06-23